Formulations of bendamustine

CAFC
  • US 9,597,398 B2
  • Filed: 01/28/2016
  • Issued: 03/21/2017
  • Est. Priority Date: 03/20/2012
  • Status: Active Grant
First Claim
Patent Images

1. A method of treating cancer or malignant disease in a subject, comprising parenterally administering a volume of about 100 ml or less of a liquid composition comprising:

  • a) from about 0.05 to about 12.5 mg/ml of bendamustine or a pharmaceutically acceptable salt thereof;

    b) a solubilizer comprising propylene glycol in an amount of from about 0.03 to about 5% by volume of the liquid composition and polyethylene glycol;

    c) a parenterally acceptable diluent; and

    optionallyd) an antioxidant;

    over a period of less than or equal to about 10 minutes to a subject in need thereof.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×